Remission of comorbidities, weight loss, and adverse events after sleeve gastrectomy and Roux-en-Y Gastric Bypass in patients with obesity

Omar Thaher 1, *, Jamal Driouch 1, Martin Hukauf 2 and Christine Stroh 3

1 Department of Surgery, Marien Hospital Herne, Ruhr-Universität Bochum, Hölkeskampring 40, 44625 Herne, Germany.
2 StatConsult gGmbH, Am Fuchsberg 11, 39112 Magdeburg, German.
3 Department of General, Abdominal and Pediatric, Surgery, Municipal Hospital, Straße des Friedens 122, 07548 Gera, Germany.
Research Article
World Journal of Advanced Research and Reviews, 2021, 12(03), 251–263
Article DOI: 10.30574/wjarr.2021.12.3.0682
Publication history: 
Received on 03 November 2021; revised on 13 December 2021; accepted on 15 December 2021
Background: Despite the extensive literature on the outcome and impact of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) on comorbidities and weight loss, clear evidence is still lacking. Our study aims to compare the short- and long-term efficacy and safety of the two procedures in patients with obesity.
Methods: The primary endpoint of this retrospective registry study is to examine the adverse events after surgery, weight loss, and remission rate of comorbidities 12 months after surgery. Any result with a p-value of ≤ 5% corresponds to a significant outcome.
Results: 27,882 patients had completed a one-year follow-up. 14,399 patients after SG and 13,483 after RYGB. The overall rate of intraoperative and postoperative complications was not significantly different between the two groups (overall p>5%). The %EWL was 62.4% in the SG group vs. 69.2% in the RYGB group; p<0.001. BMI reduction and mean weight loss were significantly different between the two groups in favor of SG.
The RYGB group achieved significantly better remission of diabetes mellitus (T2DM; p<0.001), hypertension (28.8% vs. 23.5%; p < 0.001) and reflux 22.3% vs. 7.8%; p<0.001). Sleep apnea remission was similar between the two groups (10.2%; p<0.001).
Conclusion: SG and RYGB are effective methods in the treatment of obesity. RYGB achieved better results in terms of remission of comorbidities and %EWL. However, further studies are needed to investigate the sustainability of weight loss and remission of comorbidities after both procedures.
Sleeve gastrectomy; Gastric bypass; Morbidity; Comorbidities; One-year follow-up
Full text article in PDF: 
Share this